American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort

S C Shiboski, C H Shiboski, L A Criswell, A N Baer, S Challacombe, H Lanfranchi, M Schiødt, H Umehara, F Vivino, Y Zhao, Y Dong, D Greenspan, A M Heidenreich, P Helin, B Kirkham, K Kitagawa, G Larkin, M Li, T Lietman, J Lindegaard, N McNamara, K Sack, P Shirlaw, S Sugai, C Vollenweider, J Whitcher, A Wu, S Zhang, W Zhang, J S Greenspan, T E Daniels, Sjögren's International Collaborative Clinical Alliance (SICCA) Research Groups, D Cox, R Jordan, D Lee, Y DeSouza, D Drury, A Do, L Scott, M Lam, J Nespeco, J Whiteford, M Margaret, I Adler, A C Smith, A M Bisio, M S Gandolfo, A M Chirife, A Keszler, S Daverio, V Kambo, Y Jiang, D Xu, J Su, D Du, H Wang, Z Li, J Xiao, Q Wu, C Zhang, W Meng, J Zhang, S Johansen, S Hamann, J Schiødt, H Holm, P Ibsen, A M Manniche, S P Kreutzmann, J Villadsen, Y Masaki, T Sakai, N Shibata, M Honjo, N Kurose, T Nojima, T Kawanami, T Sawaki, K Fujimoto, E Odell, P Morgan, L Fernandes-Naglik, B Varghese- Jacob, S Ali, M Adamson, S Seghal, R Mishra, V Bunya, M Massaro-Giordano, S K Abboud, A Pinto, Y W Sia, K Dow, E Akpek, S Ingrodi, W Henderson, C Gourin, A Keyes, M Srinivasan, J Mascarenhas, M Das, A Kumar, P Joshi, R Banushree, U Kim, B Babu, A Ram, R Saravanan, K N Kannappan, N Kalyani, S C Shiboski, C H Shiboski, L A Criswell, A N Baer, S Challacombe, H Lanfranchi, M Schiødt, H Umehara, F Vivino, Y Zhao, Y Dong, D Greenspan, A M Heidenreich, P Helin, B Kirkham, K Kitagawa, G Larkin, M Li, T Lietman, J Lindegaard, N McNamara, K Sack, P Shirlaw, S Sugai, C Vollenweider, J Whitcher, A Wu, S Zhang, W Zhang, J S Greenspan, T E Daniels, Sjögren's International Collaborative Clinical Alliance (SICCA) Research Groups, D Cox, R Jordan, D Lee, Y DeSouza, D Drury, A Do, L Scott, M Lam, J Nespeco, J Whiteford, M Margaret, I Adler, A C Smith, A M Bisio, M S Gandolfo, A M Chirife, A Keszler, S Daverio, V Kambo, Y Jiang, D Xu, J Su, D Du, H Wang, Z Li, J Xiao, Q Wu, C Zhang, W Meng, J Zhang, S Johansen, S Hamann, J Schiødt, H Holm, P Ibsen, A M Manniche, S P Kreutzmann, J Villadsen, Y Masaki, T Sakai, N Shibata, M Honjo, N Kurose, T Nojima, T Kawanami, T Sawaki, K Fujimoto, E Odell, P Morgan, L Fernandes-Naglik, B Varghese- Jacob, S Ali, M Adamson, S Seghal, R Mishra, V Bunya, M Massaro-Giordano, S K Abboud, A Pinto, Y W Sia, K Dow, E Akpek, S Ingrodi, W Henderson, C Gourin, A Keyes, M Srinivasan, J Mascarenhas, M Das, A Kumar, P Joshi, R Banushree, U Kim, B Babu, A Ram, R Saravanan, K N Kannappan, N Kalyani

Abstract

Objective: We propose new classification criteria for Sjögren's syndrome (SS), which are needed considering the emergence of biologic agents as potential treatments and their associated comorbidity. These criteria target individuals with signs/symptoms suggestive of SS.

Methods: Criteria are based on expert opinion elicited using the nominal group technique and analyses of data from the Sjögren's International Collaborative Clinical Alliance. Preliminary criteria validation included comparisons with classifications based on the American–European Consensus Group (AECG) criteria, a model-based “gold standard”obtained from latent class analysis (LCA) of data from a range of diagnostic tests, and a comparison with cases and controls collected from sources external to the population used for criteria development.

Results: Validation results indicate high levels of sensitivity and specificity for the criteria. Case definition requires at least 2 of the following 3: 1) positive serum anti-SSA and/or anti-SSB or (positive rheumatoid factor and antinuclear antibody titer >1:320), 2) ocular staining score >3, or 3) presence of focal lymphocytic sialadenitis with a focus score >1 focus/4 mm2 in labial salivary gland biopsy samples. Observed agreement with the AECG criteria is high when these are applied using all objective tests. However, AECG classification based on allowable substitutions of symptoms for objective tests results in poor agreement with the proposed and LCA-derived classifications.

Conclusion: These classification criteria developed from registry data collected using standardized measures are based on objective tests. Validation indicates improved classification performance relative to existing alternatives, making them more suitable for application in situations where misclassification may present health risks.

Copyright © 2012 by the American College of Rheumatology.

Figures

Figure 1
Figure 1
Area-proportional Venn diagrams visualizing the interrelationships between abnormal Ocular Staining Score, labial salivary gland focus scores ≥ 1, and positive anti-SSA and/or anti-SSB antibodies or [+RF and ANA ≥ 1:320]. The diagram is based on 1507 individuals with complete data on the variables (3 objective tests) represented. The 303 individuals not included in the shaded regions did not possess any of the three defining characteristics.

References

    1. Bloch KJ, Buchanan WW, Wohl MJ, Bunim JJ. Sjögren’s Syndrome. A Clinical, Pathological, and Serological Study of Sixty-Two Cases. Medicine (Baltimore) 1965;44:187–231.
    1. Shearn MA. Major Problems in Internal Medicine. Vol. 2. Philadelphia: WB Saunders; 1971. Sjögren’s syndrome.
    1. Daniels TE, Silverman S, Jr, Michalski JP, Greenspan JS, Sylvester RA, Talal N. The oral component of Sjögren’s syndrome. Oral Surg Oral Med Oral Pathol. 1975;39(6):875–85.
    1. Ohfuji T. Review on research reports. Annual report of the ministry of Health and Welfare: Sjögren’s disease Research Committee; Japan. 1977.
    1. Homma M, Tojo T, Akizuki M, Yamagata H. Criteria for Sjögren’s syndrome in Japan. Scand J Rheumatol Suppl. 1986;61:26–7.
    1. Manthorpe R, Frost-Larsen K, Isager H, Prause JU. Sjögren’s syndrome. A review with emphasis on immunological features. Allergy. 1981;36(3):139–53.
    1. Skopouli FN, Drosos AA, Papaioannou T, Moutsopoulos HM. Preliminary diagnostic criteria for Sjögren’s syndrome. Scand J Rheumatol Suppl. 1986;61:22–5.
    1. Fox RI, Robinson CA, Curd JG, Kozin F, Howell FV. Sjögren’s syndrome. Proposed criteria for classification. Arthritis Rheum. 1986;29(5):577–85.
    1. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, et al. Preliminary criteria for the classification of Sjögren’s syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum. 1993;36(3):340–7.
    1. Fujibayashi T. Revised diagnostic criteria for Sjögren’s syndrome. Rheumatology (Oxford) 2000;24:421–8.
    1. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554–8.
    1. Daniels TE, Criswell LA, Shiboski C, Shiboski S, Lanfranchi H, Dong Y, et al. An early view of the international Sjögren’s syndrome registry. Arthritis Rheum. 2009;61(5):711–4.
    1. Classification and Response Criteria Subcommittee of the American College of Rheumatology Committee on Quality Measures. Development of Classification and Response Criteria for Rheumatologic Diseases. Arth Rheum. 2006;55:348–52.
    1. Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and guidelines for use. Am J Public Health. 1984;74(9):979–83.
    1. Daniels TE, Cox D, Shiboski CH, Schiødt M, Wu A, Lanfranchi H, et al. Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjögren’s syndrome among 1,726 registry participants. Arthritis Rheum. 2011;63(7):2021–30.
    1. Feenstra RP, Tseng SC. Comparison of fluorescein and rose bengal staining. Ophthalmology. 1992;99(4):605–17.
    1. Whitcher JP, Shiboski CH, Shiboski SC, Heidenreich AM, Kitagawa K, Zhang S, et al. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjögren’s Syndrome International Registry. Am J Ophthalmol. 2009;149(3):405–15.
    1. Chow S, FR Drawing Area-Proportional Venn and Euler Diagrams. 11th International Symposium on Graph Drawing, Perugia, Italy Lecture Notes in Computer Science. 2003;2912:466–477.
    1. Goodman LA. Exploratory Latent Structure Analysis Using Both Identifiable and Unidentifiable Models. Biometrika. 1974;61:215–231.
    1. Pepe MS, Janes H. Insights into latent class analysis of diagnostic test performance. Biostatistics. 2007;8(2):474–84.
    1. Qu Y, Tan M, Kutner MH. Random effects models in latent class analysis for evaluating accuracy of diagnostic tests. Biometrics. 1996;52(3):797–810.
    1. Hartigan JA. In: Clustering Algorithms. Sons JW, editor. 1975.
    1. Baughman AL, Bisgard KM, Cortese MM, Thompson WW, Sanden GN, Strebel PM. Utility of composite reference standards and latent class analysis in evaluating the clinical accuracy of diagnostic tests for pertussis. Clin Vaccine Immunol. 2008;15(1):106–14.
    1. See CW, Alemayehu W, Melese M, Zhou Z, Porco TC, Shiboski S, et al. How reliable are tests for trachoma? A latent class approach. Invest Ophthalmol Vis Sci. 2011
    1. Breiman L. Random forests. Machine learning. 2001;45:5–32.
    1. Daniels T, Greenspan JS, Cox D, Criswell LA, DeSouza Y, Dong Y. Objective Measures in Sjögren’s Syndrome Associated with each other but not with Sicca Symptoms; Analysis of 564 Enrollees in the SICCA International Registry and Repository. Arthritis Rheum. 2007;56(9):S446.
    1. Masaki Y, Dong L, Kurose N, Kitagawa K, Morikawa Y, Yamamoto M, et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis. 2009;68(8):1310–5.
    1. Theander E, Vasaitis L, Baecklund E, Nordmark G, Warfvinge G, Liedholm R, et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren’s syndrome. Ann Rheum Dis. 70(8):1363–8.
    1. Moutsopoulos HM, Webber BL, Vlagopoulos TP, Chused TM, Decker JL. Differences in the clinical manifestations of sicca syndrome in the presence and absence of rheumatoid arthritis. Am J Med. 1979;66(5):733–6.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe